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ABSTRACT 
Objective. The WEGENT trial and other short-term studies suggested that azathioprine 
or methotrexate could effectively maintain granulomatosis with polyangiitis (GPA) or 
microscopic polyangiitis (MPA) remission. Whether differences in relapse or adverse event 
rates would appear after discontinuation of those 2 maintenance regimens and longer follow-
up remains unknown. 
Methods. Long-term outcomes for the patients enrolled in the WEGENT trial were 
analyzed according to their randomization group. Parameters at trial entry were evaluated as 
potential prognostic factors for death, relapse or damage in multivariate models. 
Results. Data were returned for 88.8% of the 126 original participants. Median [95% 
confidence interval] followup was 11.9 [11.3‒12.5] years. For the azathioprine and 
methotrexate arms, respectively, the 10-year overall survival rates were 75.1% [64.8–86.9] 
and 79.9% [70.3–90.8] (P = 0.56), and relapse-free survival rates 26.3% [17.3–40.1] and 
33.5% [23.5–47.7] (P = 0.29). No between-arm differences were observed for relapse, 
adverse events, damage, survival rates without severe side effects and survival rates without 
relapse and severe side effects. Considering only the 97 GPA patients, no between-arm 
survival differences were observed. Relapse-free survival was shorter for GPA than MPA 
patients but the multivariate analysis retained anti-PR3–ANCA-positivity, and not GPA, as 
being independently associated with relapse. 
Conclusion. This long-term analysis confirms that azathioprine and methotrexate are 
comparable options for maintaining GPA or MPA remission. Despite good overall survival, 
relapses, adverse events and damage remain matters of concern and further studies are needed 
to reduce them. 
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The introduction of cyclophosphamide (CYC) and glucocorticoids in the 1950s 
dramatically improved prognoses of antineutrophil cytoplasm antibody (ANCA)-associated 
vasculitides (AAVs) (1). For granulomatosis with polyangiitis (Wegener’s) (GPA), 74–80% of 
patients now survive 5 years (2–4), compared with ~70% 1-year mortality for untreated patients 
(5). Similarly, for microscopic polyangiitis (MPA), the 5-year survival rate reaches 65–95%, 
depending on the prognostic factors considered (6–8). However, those advances were achieved at 
the cost of treatment-related toxicity (9). 
The development of a 2-staged approach, using CYC (10), and later rituximab (11,12), for 
induction, and a less toxic remission-maintenance regimen to limit cumulative CYC exposure, 
was a major step forward in GPA and MPA treatment. Maintenance usually combines low-dose 
glucocorticoids and azathioprine (AZA) or methotrexate (MTX) (10–18). The prospective, 
multicenter, randomized, open-label, WEGENT trial, conducted by the French Vasculitis Study 
Group, evaluated the safety and efficacy of AZA versus MTX, combined with prednisone, as 
maintenance therapy for severe GPA or MPA, after complete remission had been achieved with 
glucocorticoids and pulse intravenous CYC (18). Trial results demonstrated that MTX was as 
safe and effective as AZA at maintaining GPA or MPA remission during 29 months of followup. 
Thus, either agent has emerged as standard care for AAV-remission maintenance (19). 
However, it remains unknown whether differences in relapse or adverse event rates would 
appear after discontinuation of those 2 maintenance regimens and longer followup. The aim of 
this followup study was to evaluate the long-term outcomes of WEGENT trial participants to 
determine whether initial AZA or MTX maintenance might be associated with fewer relapses, 
less toxicity and better long-term survival. Clinical and laboratory parameters at trial entry were 
also tested as potential prognostic factors in multivariate models for survival, relapse-free 
survival, relapse or damage. 
 
PATIENTS AND METHODS 
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Study eligibility criteria. The WEGENT trial was conducted from November 1998 
through February 2005 in France and Belgium (18). Briefly, it included patients with newly 
diagnosed GPA or MPA according to the Chapel Hill nomenclature (20,21). In addition, patients 
had to have severe GPA, defined as renal disease, involvement of ≥2 organs or systems, or 
involvement of 1 organ or system and constitutional symptoms; or severe MPA with ≥1 poor-
prognosis items of the Five-Factor Score (FFS) (serum creatinine >140 µmol/liter, proteinuria >1 
g/day, specific cardiomyopathy, gastrointestinal tract and/or central nervous system involvement) 
(22). 
Treatment protocol. All patients received daily intravenous (IV) methylprednisolone for 3 
days, followed by oral prednisone (1 mg/kg/day) for 3 weeks, then progressively tapered 
according to a predefined schedule to obtain complete cessation after 27 months. CYC pulses 
were administered until remission, followed by 3 additional consolidation pulses. Patients who 
entered remission were randomized after the 3rd consolidation to receive oral maintenance with 
12 months of AZA (2 mg/kg/day) or MTX (progressively increased to 25 mg/week). The study 
primary analysis was conducted when the last enrolled patient completed maintenance therapy, 
yielding a median followup of 29 months for the entire population. After the end of the study, 
treatment, including for potential relapses, was left to the treating physician’s discretion. 
Evaluations. The original protocol scheduled long-term analysis at 10 years of followup. 
Long-term outcomes were ascertained for the 126 enrolled patients. A questionnaire, sent to 
participating physicians, requested information on survival, relapse, cancer, infection, 
cardiovascular morbidity, damage, immunosuppressant use and death. Patients’ medical charts 
were also examined to complete discordant or incomplete information. Replies were collected 
from October 2013 until September 2014. Demographic, clinical and laboratory parameters at 
inclusion were analyzed in multivariate models as potential prognostic factors for survival, 
relapse or damage. 
This followup study was performed in accordance with the 1964 Declaration of Helsinki 
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and subsequent amendments. The Île-de-France III Ethics Committee approved the study in 
accordance with national legislation. 
Study endpoints. The primary endpoint was defined as the 10-year overall survival. Other 
judgment criteria were: relapse, major relapse, any adverse event, severe adverse event, infection, 
damage assessed with the Vasculitis Damage Index (VDI) (23), relapse-free survival and event-
free survival, i.e., the probability of surviving without suffering a relapse or severe adverse event. 
Vasculitis activity was assessed with the Birmingham Vasculitis Activity Score (BVAS) 
version 3 (24). The following definitions were applied: remission: the absence of signs of 
“new/worsening” disease activity, with BVAS = 0 (25); relapse: the reoccurrence or new 
appearance of disease activity attributable to active vasculitis (26); a major relapse: the 
reoccurrence or new onset of potentially organ- or life-threatening disease activity that cannot be 
treated with increased glucocorticoids alone and requires further therapeutic escalation (26). 
Adverse events were graded 1–4, according to World Health Organization toxicity criteria, with 
grades 3 and 4 considered severe (27). A serious infection was defined as life-threatening, 
requiring IV antibiotics or hospitalization. 
Statistical analyses. All trial participants’ data were analyzed according to the assigned 
randomization group. Followup began at WEGENT trial inclusion and continued until the last 
medical update, death or 10 years post-inclusion, whichever occurred first. Events were defined 
as death, relapses (major or not) and serious adverse events. Frequencies of adverse events, 
serious adverse events, infections, cancers, relapses and major relapses were compared with 
robust Poisson regression analyses. Numbers of relapses, major relapses and damaged organs 
were compared using negative binomial regressions. Those analyses were adjusted to followup 
time, added as an offset term in the respective models. Overall survival, relapse-free survival and 
event-free survival were analyzed with the Kaplan–Meier method and compared using log-rank 
tests. 
Demographic, clinical and laboratory parameters at inclusion were analyzed in multivariate 
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models as potential prognostic factors for survival, relapse-free survival, relapse or damage. 
Multivariate analyses used Cox models to estimate hazard ratios (HRs) and their confidence 
intervals (CIs). A multistate model was used to account for multiple relapses per patient and 
distinguish between the 2 competing events: death and relapse (28). A competing-risk model was 
used because a disease-severity variable associated with death can also be associated with 
relapse, meaning that patients with a risk factor for relapse might be censored early due to death 
in traditional time-to-event analyses, thereby obscuring the association of those risk factors with 
relapses. Forty-five imputations run for risk-factor evaluation were analyzed in 2 steps: variables 
with P <0.20 in a univariate analysis were selected for possible inclusion in the multivariate 
model, and stepwise selection based on Akaike’s information criterion considered all the selected 
factors in the stacked dataset (29). All analyses were truncated at 10 years of followup and 
computed with R statistical software v3.0.1 (30). 
 
RESULTS 
Among the 126 patients (median age 61 years) randomized in the original study (Figure 
1), 97 (77%) patients had GPA and 29 (23%) MPA. Anti-proteinase-3 (PR3) ANCA were found 
in 76 (60%) patients, while anti-myeloperoxidase (MPO) ANCA were detected in 39 (31%). 
Ten-year data were available for 112/126 (88.8%) patients and were missing for 14 after a 
median followup of 7.0 (interquartile range (IQR) 5.1–9.1) years. Median followup was 11.9 
[95% CI 11.4–12.4] years. Clinical outcomes according to treatment group are summarized in 
Table 1. 
Overall survival. Fifteen AZA-group and 12 MTX-arm patients died during followup, 
with, respectively, 1 and 2 deaths during the original trial’s followup. The primary endpoint, 
defined as the 10-year overall survival rate, did not differ significantly for the AZA (75.1%) and 
MTX arms (79.9%) (Figure 2A and B). Causes of AZA-group deaths, censored at 10 years, 
included 6 cancers, 3 cardiac causes, 1 alveolar hemorrhage, 1 end-stage renal disease (ESRD), 1 
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pulmonary embolism, 1 trauma and 2 unknown causes. MTX-arm deaths were attributed to 1 
cancer, 4 cardiac causes, 4 infections, 1 ESRD, 1 pulmonary embolism and 1 Alzheimer’s 
disease. 
Multivariate analysis retained advancing age as the only factor significantly associated 
with increased risk of death (HR 1.09 [95% CI 1.05–1.14]; P <0.001), with each additional year 
increasing the probability of death by 9% (Figure 2C). Lung involvement (affecting 75% of our 
patients at baseline), neurologic, cardiovascular or digestive involvement, impaired kidney 
function, AAV (GPA versus MPA) (Figure 2D), ANCA status (PR3 versus MPO or no ANCA) 
and BVAS-assessed disease activity at inclusion had no statistically significant impact on 
survival. 
Relapses. During followup, ≥1 relapses occurred in ~60% of AZA-group and 54% of 
MTX-arm patients before the 10-year censoring date, with respective first relapses in 31/38 
(81.6%) and 30/34 (88.2%) only after terminating maintenance. No between-arm differences 
were found for the total numbers of relapses and major relapses per patient, and the relapse or 
major relapse rates. The risk of relapse adjusted to followup duration until the first event was 
comparable for both arms. Ten-year relapse-free survival rates for the AZA and MTX arms did 
not differ significantly (Figure 3A). 
ANCA status (anti-PR3 versus anti-MPO or no ANCA) was a more powerful predictor of 
relapse-free survival and relapse than disease subtype (GPA versus MPA) (Figure 3B). 
Moreover, AAV was not significantly associated with either relapse parameter in multivariate 
analyses. Neither CYC duration nor cumulative dose was associated with relapse-free survival. 
In the multistate model accounting for all relapses, baseline anti-PR3–ANCA-positivity was the 
strongest factor significantly associated with relapses (Table 2). High initial serum creatinine 
decreased the probability of relapse, with each additional 10 µmol of creatinine/liter lowering the 
relapse risk by 1%. The glucocorticoid dose at the end of maintenance therapy or thereafter 
increased that risk. In this multivariate model, AAV, its BVAS-assessed activity at baseline and 
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the CYC pulse number or cumulative dose (g) for remission-induction before randomization did 
not affect the relapse rate. 
Adverse events. During the 10-year censured followup, no long-term between-arm 
differences were observed for severe adverse events, serious infections or cancer. 
Thirty-three (26%) patients developed serious infections requiring hospitalization, with 
the infection leading to the deaths of 4 (3%) of them. The 10-year AZA-group and MTX-arm 
severe side-effect–free and event-free survival rates were comparable. 
During long-term followup, the following cancers were observed: in the AZA arm: 6 
adenocarcinomas, including 3 colorectal, 1 stomach, 1 breast and 1 ovarian cancer; 1 bladder 
cancer (after a cumulative total CYC dose of 8 g); 1 squamous cell carcinoma of the lung; 1 
cerebral glioblastoma; 1 cutaneous melanoma and 1 cutaneous basal cell cancer; in the MTX 
arm: 5 adenocarcinomas, including 2 colorectal, 2 ovarian and 1 uterine cancer; 1 small-cell lung 
carcinoma; 1 hepatocellular carcinoma without viral hepatitis infection; 1 cutaneous squamous 
cell carcinoma and 1 cutaneous basal cell carcinoma. 
Duration of immunosuppression. All patients received their assigned AZA or MTX 
maintenance according to the trial protocol for comparable times and glucocorticoid durations of 
intake were also similar for the 2 arms. Table 3 summarizes the post-trial treatments patients 
received during long-term followup. Neither the numbers of treated patients nor the estimated 
mean cumulative cyclophosphamide or rituximab doses for AAV relapse differed significantly 
between arms. 
At the last update for AZA and MTX arms, respectively, data on glucocorticoids and 
other immunosuppressants were missing for 8 and 6 patients; 29 patients in each group were still 
taking prednisone (median respective doses: 7.0 and 5.0 mg/day); 20 and 18 patients were still 
taking other immunosuppressants, mainly MTX (12 patients), rituximab (11 patients) and AZA 
(8 patients); and, finally, 28 and 27 patients were no longer taking any immunosuppressant. 
Renal function. No significant between-arm difference was observed for renal function or 
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ESRD, with 7 (11.1%) AZA-group and 8 (12.7%) MTX-arm patients developing ESRD. 
Although all these 15 patients had initial renal involvement, 3 of them had creatinine <100 
µmol/liter at inclusion. Those 15 patients had 24 relapses, 16 of which included renal 
involvement. In addition, 4 patients required transient dialysis at AAV onset or at relapse; with 
median follow-up of 11 years, their mean ± SD creatinine value and glomerular filtration rate 
(GFR) at last follow-up was 159 ± 27 µmol/liter and 34 ± 6 ml/min, respectively. 
Among the 93 (47 AZA and 46 MTX, respectively) patients without ESRD and whose 
renal parameters were available at last update, mean serum creatinine levels (111.4 [range 55–
273] and 105.9 [range 49–276] µmol/liter) and mean GFR (59.5 and 61.3 ml/min) did not differ 
significantly. 
Damage. At the last update, accrued damage was severe in both arms but mean VDI 
scores were similar for the 2 study arms. Multivariate analysis adjusted to followup duration 
retained age, baseline anti-PR3–ANCA-positivity versus anti-MPO–ANCA or none, initial 
creatinine level and glucocorticoid dose at the end of the maintenance as being significantly 
associated with VDI-assessed damage (Table 2). 
Survival analysis of GPA patients alone and versus MPA patients. Considering only 
the 97 GPA patients, the AZA and MTX arms did not differ significantly for overall survival, 
relapse-free survival, survival without major relapse, survival without severe side effects or 
event-free survival. 
For GPA versus MPA, respectively, the 10-year overall survival rates (75.1% [95% CI 
66.8–84.5] and 85.2% [95% CI 72.8–99.8]) did not differ significantly (HR 1.84 [95% CI 0.64–
5.33) (Figure 2D). Ten-year relapse-free survival was shorter for GPA than MPA patients (23.3% 
[95% CI 16.2–33.7] versus 51.7% [95% CI 36.4–73.5], respectively; HR 2.20 [95% CI 1.24–
3.91]; P = 0.007) but multivariate analysis did not retain GPA as being independently associated 
with relapse. 
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DISCUSSION 
The WEGENT trial was undertaken to compare the safety and efficacy of MTX versus 
AZA as GPA or MPA remission-maintenance therapy. Both drugs appeared to be equivalent 
alternatives to maintain remission at 29 months and our long-term analysis results further 
confirm our original findings (18). Whereas overall survival was good, relapses, adverse events 
and damage were common. 
Survival of our severe GPA patients is consistent with previous studies, but 10-year 
survival data for MPA patients were lacking. The prolonged followup of WEGENT-trial patients 
yielded 10-year overall survival rates of 75.1% for GPA and 85.2% for MPA patients, 
comparable to the 80% reported for the 158 GPA patients enrolled in the NIH cohort study but 
after mean followup of only 8 years (9); 75% for the 56 GPA patients included in another study 
(2); and 88% for a cohort of 155 consecutive GPA patients (followup 6.6 years), 24 with 
localized disease (31), and 86% of 148 GPA patients (followup 4 years), 18 with localized 
disease, participating in a single-center cohort study (32). Reported 5-year survival of MPA 
patients ranged between 45% and 76% in 5 studies that included 217 MPA patients (33). The 
higher MPA survival rate observed herein, despite the inclusion of only patients with severe 
disease (FFS ≥1), fully supports the usefulness of therapy adapted to the prognostic FFS and 
further validates it for severe MPA. 
In our long-term study, overall survival was comparable for GPA and MPA patients, in 
accordance with another large, long-term study (34). Differences noted in earlier investigations 
(35,36) may have reflected either the reporting of crude mortality, without adjusting for MPA 
patients’ older age, underpowered multivariate analyses and/or inadequate case-mix (34). 
According to our multivariate analysis, advancing age was the sole factor significantly 
associated with death, as identified in previous GPA studies (2,3,31). The only other study that 
identified prognostic baseline factors for survival in a cohort of GPA patients receiving 
homogeneous care found age, kidney and lung involvement to be associated with poorer survival 
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(31). For MPA, age, renal and severe gastrointestinal involvement were reported to be the main 
significant indicators of diminished survival (6,37). All those are items included in the revised 
FFS, which is also applicable to GPA and MPA (38). 
Although the induction-maintenance approach to treat GPA and MPA undoubtedly 
represents an important therapeutic advance, the frequent relapses (half to two-thirds of our 
participants at 10 years) still pose a challenge for their long-term management. Indeed, 10-year 
relapse-free survival was only 26.3% and 33.5% for the AZA and MTX recipients, respectively. 
These low rates are consistent with other long-term studies on GPA (24% at 5 years) (39) and 
MPA (45.4% and 43.4% at 7 years) (7,8). Anti-PR3–ANCA-positivity has repeatedly been 
shown to be associated with a higher relapse risk for AAV cohorts (40–43) or other randomized–
controlled trials (44–46), in agreement with our findings. Although GPA patients reportedly 
relapsed more frequently than those with MPA (10), it must be emphasized that our multivariate 
analysis retained baseline anti-PR3–ANCA-positivity, but not GPA, as being independently and 
significantly prognostic of recurrent relapses and, thus, negatively affected relapse-free survival. 
Thus, the more frequent cumulative GPA relapses might be linked to the more frequent presence 
of those antibodies in these patients. This notion supports those found in a study including 
patients with renal disease (42). Our results also retained high serum creatinine levels as being 
independently associated with significantly fewer relapses. That finding corroborates 
observations based on 2 large AAV cohorts: relapses of 535 European and 439 Chinese patients 
were inversely associated with the serum creatinine concentration (43,47). Patients with impaired 
renal function, who are less prone to relapse but have an increased risk of death due to treatment 
side effects (48), might be better treated with milder immunosuppression. This hypothesis should 
be investigated prospectively. 
The WEGENT protocol required stopping glucocorticoids after a 2-year total duration. That 
glucocorticoid dose and duration were associated with heightened risk of relapse in our study 
might be explained by physicians being more likely to continue glucocorticoids or delay their 
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dose-tapering, when vasculitis remains in remission but atypical signs or symptoms appear or 
acute-phase reactants increase, possibly due to an intercurrent affection, or perhaps immediately 
preceding relapse. Meta-analysis results showed that trials in which glucocorticoids were not 
scheduled for withdrawal (usually continuing prednisone at 5–7.5 mg/day) or were routinely 
prescribed for >18 months (mostly European studies) had markedly lower relapse rates than 
those in which they were discontinued earlier by month 6–12 (including most U.S. studies) (49). 
On the other hand, our findings demonstrated that glucocorticoid dose at the end of the 
maintenance was associated with higher accrued damage, consistent with previous observations 
(2). Thus, optimal glucocorticoid duration needs to be examined in randomized–controlled trials 
analyzing both relapse rate and accrued damage. 
In the WEGENT trial, the study drug had to be discontinued after 12 months of 
maintenance therapy and >80% of our patients’ first relapses in each arm occurred only after 
treatment withdrawal, as previously reported (9,50). Patients initially anti-PR3–ANCA-positive 
are at higher risk of relapse and may require longer maintenance therapy to limit this risk. Results 
of a retrospective study showed, among newly diagnosed GPA patients, that longer maintenance 
therapy was associated with fewer relapses, even after adjusting for prednisone use (50). Because 
of limited power, a prospective controlled trial was unable to confirm significantly different 
relapse-free survival among patients persistently positive for cytoplasm-labeling ANCA at 
remission randomized to receive either standard or extended maintenance therapy (51). The 
results of the randomized REMAIN trial, comparing 18–24 months versus 4 years of treatment, 
should help better define optimal maintenance-therapy duration for different AAVs (52). 
Further investigation is needed to optimize maintenance regimens. In our group’s recently 
published randomized–controlled MAINRITSAN trial, the reinfusion of fixed-interval low-dose 
rituximab (0.5 g every 6 months until month 18) better prevented GPA or MPA relapses than 22 
months of azathioprine and represents a significant advance, particularly for anti-PR3–ANCA-
positive patients who are more prone to relapse (53). 
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Severe adverse events remain frequent during the long-term followup of these patients, 
with a quarter of them developing serious infections. The same percentage was observed in the 
German cohort (31), as opposed to 46% of the NIH cohort (9). Infection led to the deaths of 3% 
of our patients, again similar to those reported for the German (31) and NIH cohorts (9). 
Our study has several notable strengths. To our knowledge, it has the longest followup 
among studies investigating survival of patients with MPA or GPA, followed for a median of 
>11 years post-inclusion in a randomized–controlled trial for newly diagnosed AAV. In addition, 
data was available for ~90% of the original trial participants. We used competing-risk analysis 
that may more easily identify some factors associated with relapse and death. Moreover, multiple 
imputations improved the resulting estimates and decreased bias due to missing data. 
Furthermore, these patients were recruited from 70 French Vasculitis Network centers and are 
therefore likely to be representative of the entire vasculitis-patient spectrum. Hence, our findings 
should be generalizable. 
Some limitations also need to be acknowledged. This original trial was not designed to 
assess the impact of the 2 regimens on long-term relapse or survival. After the year-long 
maintenance therapy, immunosuppressant use was left to the treating physician. One cannot 
exclude that a difference between the 2 drugs, in terms of efficacy and/or safety, could be 
observed at a later date if they were taken for a longer duration. Our study may have been 
underpowered to detect a higher risk of death associated with initial cardiovascular involvement 
or severe renal impairment because too few affected patients were included. This long-term 
followup study was retrospective, with all the inherent potential biases associated with 
retrospective data collection. However, questionnaire-response rates were high and patients’ 
medical charts were also reviewed to complete discordant or incomplete information, leading to 
the availability of long-term data for ~90% of the participants. So, despite being retrospective, 
we think that significant ascertainment bias is unlikely. 
In conclusion, this long-term analysis confirms that MTX and AZA are comparable 
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options for maintaining GPA or MPA remission. Despite good overall survival, relapses, adverse 
events and damage continue to be persistent concerns in AAV patients. Longer maintenance 
treatment, at least for anti-PR3–ANCA-positive patients should be evaluated prospectively, as 
well as newer strategies to decrease relapse and damage rates. 
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APPENDIX 
In addition to the authors, the following FVSG investigators and members (listed alphabetically 
by city) participated in the study (all in France unless specified otherwise): Centre Hospitalier 
(CH), Agen: P Rispal; CH, Alençon: N Baidi, O Chrétien; CH Universitaire (CHU), Hôpital 
Nord, Amiens: R Cevallos, J-P Ducroix; Amou: J-G Darmaillacq; CHU, Angers: F Dubas†, M-N 
Maghakian, C Moreau; CH, Argentan: C Dubos-Arvis; Cliniques du Sud Luxembourg, Arlon, 
Belgium: R Frognier; CH, Avignon: P Gobert, J Pollini; Beaune: D Pingat; CH, Beaune: L Janin-
Manificat; CH, Blois: B Lafon; Hôpital Jean-Verdier, Bondy: A Kettaneh; CHU Pellegrin, 
Bordeaux: M Moiton, JM Ragnaud; CH, Bourg-en-Bresse: C Boudray, B Raphanel, J-P Renand; 
CH Pierre-Oudot, Bourgoin-Jallieu: M Roux; Bouzy: G Bonnaire; Branne: A Guiso; CHU, Brest: 
JM André, R Perrichot; Broglie: J Louvet; CHU Clémenceau, Caen: N Artigues, B Bienvenu, B 
Hurault de Ligny, C Le Hello, P Letellier, T Lobbedez, Y Ollivier, M Pujo, J-P Ryckelynck; CH 
René-Dubos, Cergy-Pontoise: J-J Montseny; Champs-sur-Marne: P Collet; CH, Charleville 
Mézières: B Ayach, J-J Dion, H Mouawad; CH, Chartres: R Damade, L Dupouët; Château 
Thébaud: K Asgaraly; Chaumont: B Depernet; Hôpital Louis-Pasteur, Cherbourg: T Colin; 
Hôpital Antoine-Béclère, Clamart: V Ioos; CHU Hôtel-Dieu, Clermont-Ferrand: V Rieu; Hôpital 
Beaujon, Clichy: N Belmatoug, L Foulon, G Jebrak; CH, Compiègne: L du Coedic; CH Laennec, 
Creil: C Bachmeyer; CHU Henri-Mondor, Créteil: A Dumoulin, B Godeau, M Khellaf, M 
Michel, M Pastural, A Schaeffer; Dammartin-en-Goële: M Geffroy; CHU, Dijon: P Bielefeld; 
CH, Dreux: D Fichet; CH, Eaubonne: J-L Saraux; Groupe Hospitalier Mutualiste, Grenoble: S 
Vinzio; Jard-sur-Mer: P Ehrlacher; CHU, Kremlin–Bicêtre: A Azria, X Mariette; CH, La Roche-
sur-Yon: M Tiab; CH, Laval: D Delansorne; CH, Le Mans: N Boullanger, F Closs-Prophette, A 
Goldstein; Le Mans: L Bouscaud; CH Robert-Boulin, Libourne: V Meunier; CHU Claude-
Huriez, Lille: E Hachulla, P-Y Hatron, D Launay; CHU Dupuytren, Limoges: C Hottelart, E 
Liozon, O Longuet, V Loustaud-Ratti, P Soria, E Vidal; CH Robert Bisson, Lisieux: L Geffray, P 
Henri, I Landru; CH Bretagne-Sud, Lorient: J-M Guillemot, J Le Noach; Hôpital Louis-Pradel, 
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Lyon: J-F Cordier, V Cottin, B Gentil; Hôpital Edouard-Herriot, Lyon: S Demolombe-Rague, M-
H Girard-Madoux, J Ninet, L Pinède; Magnac Laval: J-P Meynieux; CHU La Timone, Marseille: 
J Serratrice, B Xeridat; CHU Nord, Marseille: D Bagnères; Hôpital de la Conception, Marseille: 
J Roudier; Montauban: B Denis; Montherme: N Boillet; CH, Montluçon: A Geraads, R 
Teyssandier; Hôpital Saint-Eloi, Montpellier: F Degraeve, A Le Quellec, S Rivière; CH, 
Morlaix: C Rogé; Mugron: J-P Fauchay; CHU, Nancy: D Wahl; CHU Hôtel-Dieu, Nantes: C 
Agard; Nantes: T Généreau, D Meker; CHU, Nice: S Bensakel; CHU Caremeau, Nîmes: F 
Vecina; Hôpital Bichat–Claude-Bernard, Paris: M Aubier, G Foulon, G Jebrak, P Lelièvre, O 
Lidove, F Mignon, O Meyer†, M Piperaud, G Queffeulou, F Vrtovsnik; Hôpital Cochin, Paris: A 
Aouba, J-P Arène, A Bérezné, V Le Guern; Groupe Hospitalier Pitié–Salpêtrière, Paris: Z 
Amoura, O Benveniste, D Dimitri, D Lê Thi Huong; Hôpital Saint-Louis, Paris: A Bergeron, A 
Bourgarit, D Farge, A Mahr, F Martinez, D Séréni; Hôpital Hôtel-Dieu, Paris: E Aslangul; 
Hôpital Tenon, Paris: C Arnal, J Cadranel, E Daugas, G Pelle, J Rossert, M Wislez; Institut 
Mutualiste Montsouris, Paris: M Gayraud; CH Intercommunal de Poissy–Saint-Germain, Poissy: 
A Bruet, Y Hillion; Hôpital Jean-Bernard, Poitiers: M Paccalin; CHU Robert-Debré, Reims: J 
Léone, J-L Pennaforte; Hôpital Bois Guillaume, Rouen: S Barbier, B Legallicier; Hôpital 
Charles-Nicolle, Rouen: S Dominique; CH, Saint-Brieuc: C Charasse, D Coëtmeur, E Duhamel; 
Saint-Brieuc: J-P Goulias; CH, Saint-Cloud: F Bournerias; Stotzheim: P Gautherie; CHU 
Hautepierre, Strasbourg: J-L Schlienger; Tourlaville: A Vidal; CHU Bretonneau, Tours: E Diot, 
P Diot; CH, Valenciennes: P Vanhille; Hôpital Saint-Nicolas, Verdun: P Bindi; Villefranche-sur-
Saone: G Cervantes. 
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Table 1. Clinical outcomes during long-term followup of WEGENT trial participants according to their initial randomization arm  
 
Azathioprine Methotrexate HR or aRR or  
aIRR [95% CI] 
 
 
P Parameter (n = 63) (n = 63) 
Months of therapy during trial, mean ± SD 
    
     Maintenance 12.5 ± 7.3 11.5 ± 5.1 
 
0.36 
     Glucocorticoids 27.0 ± 6.4 26.7 ± 7.8 – 0.86 
Years of followup, median [95% CI] 11.9 [11.3–12.5] 12.0 [11.2–12.5] – 0.81 
Patients lost-to-followup* 
   
 
     No. 8 6 – 0.57 
     Years of followup, median [range] 7.7 [4.9–9.8] 5.0 [2.7–9.7] – 0.28 
Deaths*, no. (%) 15 (23.8) 12 (19.0) 0.80† [0.37–1.71] 0.56 
Patients with*  
   
 
     ≥1 relapses, no. (%; cases/100 person-years) 38 (60.3; 12.5) 34 (54.0; 9.8) 0.78‡ [0.13–4.85] 0.35 
     ≥1 severe adverse events, no. (%; cases/100 person-years) 33 (52.4; 7.9) 35 (55.6; 8.3) 1.05‡ [0.70–1.58] 0.84 
     ≥1 serious infections, no. (%; cases/100 person-years) 16 (25.8; 3.4) 22 (34.9; 4.8) 1.40‡ [0.20–9.80]  0.32 
     ≥1 malignancies, no. (%; cases/100 person-years) 11 (17.7; 2.2) 10 (15.9; 1.9) 0.90‡ [0.56–1.47] 0.81 
Patients with end-stage renal disease*, no. (%) 7 (11.0) 8 (12.7) – 0.78 
Relapse* 
   
 
     No. 80 67 – – 
     Mean no. (± SD) per patient 1.3 ± 1.4 1.0 ± 1.3 0.83§ [0.55–1.25] 0.38 
     Major, no. 58 51 – – 
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     Major, mean no. (± SD) per patient 0.9 ± 1.2 0.8 ± 0.9  0.81§ [0.53–1.26] 0.35 
     First only after stopping study maintenance drug, no. (%) 31/38 (81.6) 30/34 (88.2) 1.08 [0.89–1.31] 0.43 
     Relapse-free survival, median [95% CI], years 3.8 [2.4‒5.5] 4.8 [3.7‒8.4]  0.29 
     Major relapse-free survival, median [95% CI], years 5.0 [2.9‒9.6] 6.3 [4.8‒9.6]  0.46 
Survival at 10-year followup* 
   
 
     Overall (%) [95% CI] 75.1 [64.8–86.9] 79.9 [70.3–90.8] 0.80† [0.37–1.71] 0.56 
     Relapse-free (%) [95% CI] 26.3 [17.3–40.1] 33.5 [23.5–47.7] 0.80† [0.52–1.21] 0.29 
     Severe side effect-free (%) [95% CI] 43.6 [32.8–58.0] 42.1 [31.4–56.4] 1.02† [0.64–1.62] 0.94 
     Relapse- and severe side effect-free (%) [95% CI] 21.9 [13.7–35.1] 21.2 [13.1–34.4] 0.96† [0.65–1.43] 0.84 
VDI per patient, mean ± SD 3.2 ± 2.5 3.1 ± 2.0 1.00§ [0.74–1.36] 1.00 
 
*Data censored at 10 years. HR = hazard ratio; aRR = adjusted relative risk on length of followup until the first event; aIRR = incidence risk ratio 
adjusted to length of followup.  
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*Data censored at 10 years. 
†Each additional 10 µmol/liter of creatinine at inclusion decreased the relapse risk by 1%. 
‡Each additional mg of prednisone at the end of maintenance increased the relapse risk by 12%. 
§Each additional 6 months of prednisone after stopping maintenance increased the relapse risk by 
3%. 
↑Each additional year increased VDI by 5%. 
£Each additional 10 µmol/liter of creatinine at inclusion increased the VDI by 3%. 
¥Each additional mg of prednisone when AZA/MTX was discontinued increased VDI by 12%. 
Table 2. Multivariate analyses of factors associated with relapses or damage* 
  
 Factor Hazard ratio [95% CI] P 
Associated with relapses 
  
     Anti-PR3ANCA (versus anti-MPOANCA or no ANCA) 1.99 [1.29‒3.08] 0.002 
     Baseline serum creatinine† 0.99 [0.98‒1.00] <0.05 
     Glucocorticoid dose at the end of maintenance‡ 1.05 [1.01‒1.09] 0.01 
     Glucocorticoid duration§ 1.03 [1.00‒1.05] 0.02 
Associated with VDI-assessed damage 
  
     Age↑ (years) 1.05 [1.02‒1.09] 0.002 
     Anti-PR3–ANCA (versus anti-MPO–ANCA or no ANCA) 2.53 [1.11‒5.76] <0.03 
     Baseline serum creatinine£ 1.03 [1.00‒1.05] <0.02 
     Glucocorticoid dose at the end of maintenance¥ 1.12 [1.01‒1.24] 0.03 
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Table 3. Post-trial treatments prescribed during long-term followup 
 
Therapy 
AZA 
n = 63 
MTX 
n = 63 
 
P 
Cyclophosphamide 
       Patients, no. 26 24 0.77 
    IV induction therapies, no. 27 23 0.51 
    Oral induction therapies, no. 10 9 0.83 
    Oral cyclophosphamide after IV induction, no. 6 5 0.77 
    Cumulative dose, mean ± SD (g) 1.2 ± 2.7 1.0 ± 2.1 0.40 
Rituximab 
       Patients, no. 10 8 0.64 
    Induction therapies, no. 10 8 0.64 
    Remission-maintenance therapies, no. 6 6 0.98 
    Cumulative dose, mean ± SD (g) 11.9 ± 15.9 9.1 ± 11.3 0.67 
GC ≥30 mg/day, no. patients 47 46 0.96 
IVIg, no. patients 9 2 0.03 
Plasma exchange, no. patients 1 0 1 
Infliximab, no. patients 1 2 0.62 
AZA = azathioprine; MTX = methotrexate; IV = intravenous; GC = glucocorticoids; IVIg = 
intravenous immunoglobulins. 
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FIGURE LEGENDS 
 
Figure 1. Design of the WEGENT trial and of its long-term followup study. Followup was from 
trial inclusion to the last medical update or death. Patients were censored 10 years after inclusion. 
AZA = azathioprine; MTX = methotrexate. 
 
Figure 2. Overall survival (A) censored at 10 years with confidence interval (---) and according 
to (B) randomization arm, (C) age or (D) vasculitis of the 126 enrolled patients in the WEGENT 
trial. AZA = azathioprine; MTX = methotrexate; MPA = microscopic polyangiitis; GPA = 
granulomatosis with polyangiitis (Wegener’s). The vertical line indicates the discontinuation of 
azathioprine or methotrexate maintenance therapy after 1 year. 
 
Figure 3. Relapse-free survival censored at 10 years according to (A) randomization arm and (B) 
ANCA status of the 126 enrolled patients in the WEGENT trial. AZA = azathioprine; MTX = 
methotrexate; ANCA status = anti-PR3 versus anti-MPO or none. The vertical line indicates the 
discontinuation of azathioprine or methotrexate maintenance therapy after 1 year. 
 
 30 
   WEGENT Trial 126 Patients achieved remission and were randomized 
63 Assigned to AZA 
1 Died 
0 Lost-to-followup 
2 Died 
0 Lost-to-followup 
63 Assigned to MTX 
63 Included in the 
primary analysis 
123 Followed with standard of care 
Figure 1. 
8 Received AZA for >16 months 
1 Withdrew 
3 Received MTX for >16 months 
14 Died 
8 Lost-to-followup 
(median followup: 7.7 years) 
Long-term followup study 
6 Lost-to-followup 
(median followup: 5.0 years) 
63 Included in the 
primary analysis 
63 Included in the 
primary analysis 
63 Included in the 
primary analysis 
10 Died 
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